<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103998</url>
  </required_header>
  <id_info>
    <org_study_id>THOP2 - NYMC - CCC</org_study_id>
    <nct_id>NCT02103998</nct_id>
  </id_info>
  <brief_title>Study of Thyroid Hormones in Prematures</brief_title>
  <acronym>THOP2</acronym>
  <official_title>Phase III Study of Thyroid Hormones in Prematures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day&#xD;
      oral potassium iodide (KI) for 42 days from birth will reduce by 30% or more (from an&#xD;
      estimated 30% to 21%) the proportion of extremely low gestational age subjects with a&#xD;
      composite endpoint of &quot;cerebral palsy (CP) or a Bayley III Composite Cognitive Score &lt; 85&quot; at&#xD;
      36 months corrected postnatal age (CA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase III multicenter, masked, placebo controlled randomized clinical trial&#xD;
      (RCT) of thyroid hormone supplementation in premature infants. Survival for extremely low&#xD;
      gestational age neonates (ELGAN; 24 - 28 weeks) has risen to &gt;80% over the past 40 years yet&#xD;
      cognitive delays or cerebral palsy (CP) still affect 30% of survivors. Since more than 25,000&#xD;
      ELGANs are born each year in the United States, a major priority in newborn medicine must be&#xD;
      to translate the gains in survival into gains in healthy survival without the current high&#xD;
      frequency of impairments. Transient hypothyroxinemia of prematurity (THOP) occurs in 50% of&#xD;
      ELGANs and is strongly associated as an independent risk factor with lower IQ scores,&#xD;
      behavioral abnormalities and CP in ELGANs. Prior evidence suggested a benefit from&#xD;
      replacement therapy but studies were underpowered to prove this. The current project extends&#xD;
      the findings of our Phase 1 trial (THOP1; R01-NS45109) where four thyroid hormone regimens&#xD;
      were tested. We showed that continuous infusion of 4 µg/Kg/day thyroxine x 42d could safely&#xD;
      correct transient hypothyroxinemia without markedly lowering TSH - creating a &quot;biochemical&#xD;
      euthyroid&quot; state. THOP2 is designed to test the primary hypothesis that compared to placebo,&#xD;
      thyroid hormone supplementation from birth will reduce from 30% to 21% the proportion of&#xD;
      subjects with a composite endpoint of &quot;CP or a Bayley III Cognitive Score &lt; 85.&quot; A Secondary&#xD;
      hypothesis is that hormone treatment will improve other measures of cognitive and executive&#xD;
      function or attention as assessed by: i) Bayley III Parent Interview for Adaptive Behavior&#xD;
      and the BRIEF-P (Behavioral Rating Inventory of Executive Function-Preschool Version) and ii)&#xD;
      the frequency of screening positive on the Modified Checklist for Autism in Toddlers&#xD;
      (M-CHAT). We plan to enroll 1,224 subjects over a 19.8 month period at 14 centers to obtain&#xD;
      388 surviving toddlers at 36 months corrected age in each of two arms. The current&#xD;
      application describes the scientific basis of the proposed overall clinical trial; it is&#xD;
      linked to a cluster application creating a Data Monitoring and Analysis Coordinating Center&#xD;
      (DCC) at Michigan State University (MSU). The additional societal cost from CP in an affected&#xD;
      person's lifetime is estimated at $1 million; the costs of mental retardation are even&#xD;
      higher. If this trial shows that an inexpensive intervention can reduce the risks of CP and&#xD;
      mental retardation by 30% in ELGANs, we estimate the overall savings from preventing more&#xD;
      than 2,000 such cases (9% of 25,000) at about $2 billion per year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    not funded by NIH&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare incidence of a COMPOSITE endpoint of &quot;cerebral palsy (CP) or a Bayley III Composite Cognitive Score &lt; 85&quot; at 36 months corrected postnatal age (CA).</measure>
    <time_frame>36 months</time_frame>
    <description>Bayley III Cognitive Score and a standardize ELGAN-type neurological exam (Kuban) plus a Palisano assessment of function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare measures of cognitive and executive function and attention.</measure>
    <time_frame>36 months corrected age</time_frame>
    <description>As assessed by the following tests:&#xD;
The mean scores of the Bayley III Parent Interview for Adaptive Behavior and the BRIEF-P (Behavioral Rating Inventory of Executive Function-Preschool Version).&#xD;
The frequency of screening positive on the Modified Checklist for Autism in Toddlers (M-CHAT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Transient Hypothyroxinemia of Prematurity (THOP)</condition>
  <arm_group>
    <arm_group_label>T4 + KI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D5W - 5% dextrose water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receive the same volume as study drug but as D5W placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thryoid hormone T4 + oral potassium iodide (KI) for 42 days</intervention_name>
    <description>Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days</description>
    <arm_group_label>T4 + KI</arm_group_label>
    <other_name>levothyroxin</other_name>
    <other_name>postassium iodide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D5W - 5% dextrose water</intervention_name>
    <description>Equivalent volume of infusion as study drug</description>
    <arm_group_label>D5W - 5% dextrose water</arm_group_label>
    <other_name>Standard hospital pharmacy solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Neonates 24 0/7 to 27 6/7 weeks gestational age&#xD;
&#xD;
          2. inborn or transferred; &lt; 24 hours old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Maternal or congenital thyroid disease or&#xD;
&#xD;
          2. Maternal substance abuse by history at the time of birth (heroin or cocaine)&#xD;
&#xD;
          3. Major congenital or surgical malformations of neonate&#xD;
&#xD;
          4. Known chromosomal anomalies detected by antepartum testing or direct physical&#xD;
             examination&#xD;
&#xD;
          5. Absence of parental consent or treating physician assent&#xD;
&#xD;
          6. A concurrent clinical trial with another randomized drug&#xD;
&#xD;
          7. Death expected &lt; 48h vi) Another concern by the treating physician that either&#xD;
             mandates or prohibits study treatment such as known adverse drug interaction&#xD;
&#xD;
          8. mother &lt; 18 years old at delivery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund F La Gamma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maria Fareri Childrens Hospital</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>La Gamma EF, van Wassenaer AG, Ares S, Golombek SG, Kok JH, Quero J, Hong T, Rahbar MH, de Escobar GM, Fisher DA, Paneth N. Phase 1 trial of 4 thyroid hormone regimens for transient hypothyroxinemia in neonates of &lt;28 weeks' gestation. Pediatrics. 2009 Aug;124(2):e258-68. doi: 10.1542/peds.2008-2837. Epub 2009 Jul 5.</citation>
    <PMID>19581264</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Edmund F LaGamma, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>extremely low gestational age neonate</keyword>
  <keyword>hypothyroxinemia of prematurity</keyword>
  <keyword>brain development</keyword>
  <keyword>cerebral palsy</keyword>
  <keyword>cognitive dealy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

